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Abstract
SARS‐CoV‐2 is highly infectious, and infection by this virus results in COVID‐19,
manifesting predominantly symptoms in the lower respiratory system. Detection
of viral genomic materials by RT‐PCR is the gold standard for diagnosis. Suspected COVID‐19 patients who had a documented history of exposure and
exhibited symptoms, but did not have positive PCR test results, were generally
self‐quarantined with prescriptions aiming to help attenuate their symptoms.
These prescriptions are however neither specific nor highly effective for
COVID‐19 treatment. Given the rapidly growing pandemic and the overwhelmed
medical system, the number of self‐quarantined patients is increasing. There is an
urgent need of alternative medicine to help patients relieve symptoms during
self‐quarantine, and to potentially help increase their chances of survival and
recovery from the infection. We report here a case of severe COVID‐19 that
never had a positive PCR test result during disease progression but was confirmed with antibody test post recovery. This patient was self‐quarantined and
received diammonium glycyrrhizinate (DG), a steroid‐like molecule, in combination with vitamin C as alternative medicine. This patient went through severe
COVID‐19 but eventually recovered upon the implementation of this treatment

Abbreviations: COVID‐19, coronavirus disease 2019; DG, diammonium glycyrrhizinate; RT‐PCR, reverse transcription polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory
syndrome coronavirus‐2; VC, vitamin C.
Hong Ding and Wenjun Deng contributed equally to this study and both should be considered as first authors.
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regimen, suggesting potential therapeutic effects of DG as alternative medicine
to help relieve COVID‐19 symptoms.
KEYWORDS

alternative medicine, antibody test positive, COVID‐19, PCR test negative, prolonged
symptoms

1 | BACKGROUND

confirmed COVID‐19 patients and also showed respiratory symptoms,
however unfortunately, their upper respiratory system did not have

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is highly

viral loads that were high enough to pass the PCR test threshold, and so

infectious,1 even when the patients show no or minor symptoms.2 In-

they did not have a positive PCR test result to qualify for hospitalization

fection by SARS‐CoV‐2 causes a broad spectrum of diseases that affects

in January and early February in Wuhan. Our medical team tracked and

multiple organs including the lung, nervous system, heart, digestive sys-

helped treat a number of these nonhospitalized COVID‐19 patients.

tem, kidney and others.3 The resultant coronavirus disease 2019

Here, we report a case of nonhospitalized COVID‐19 that never

(COVID‐19) manifests predominantly symptoms in the lower respiratory

had a positive PCR test result during disease progression and recovery.

system, typically presented as viral pneumonia. Detection of viral geno-

This patient was confirmed as a COVID‐19 case, by SARS‐CoV‐2‐

mic materials is the gold standard for diagnosis. Standard operation

specific antibody test post recovery. This severe COVID‐19 patient was

procedures use pharyngeal swabbing samples from the upper respiratory

self‐quarantined and received diammonium glycyrrhizinate (DG), a

system, which may miss the anatomic location of viral replication, leading

marketed Chinese traditional medicine with a steroid‐like effect, in

to false negative diagnostic result.4 The unexpected pandemic outbreak

combination with vitamin C (VC) as alternative medicine. Upon im-

also resulted in deprivation of medical resources in the peak phase in

plementation of this treatment regimen, the patient's symptoms were

areas that did not have sufficient preparation and/or resources. Sus-

significantly relieved and eventually recovered. In this article, we aim to

pected COVID‐19 patients who had documented history of exposure and

report more details of this encouraging case and bring DG to the table

exhibited symptoms, but did not have positive polymerase chain reaction

for discussion about its potential as an alternative medicine to attenuate

(PCR) test results, were generally self‐quarantined. Some patients had a

COVID‐19 symptoms in nonhospitalized patients. Of note, this case is

contact history with a confirmed COVID‐19 patient but did not have

not a clinical trial, and we decided to share this information with the

typical viral pneumonia symptoms or fever, and so did not get selected

hope of increasing treatment options for patients who cannot be

for PCR testing. Given the rapidly growing pandemic and the over-

“diagnosed” with PCR test, are turned down by hospitals and have to

whelmed medical system, a number of patients with typical COVID‐19

seek alternative medicine for COVID‐19 symptoms.

symptoms could not be hospitalized, even if they were tested positive by
PCR. The combination of the false negative rate of PCR testing, the
biased pre‐screening procedure for patients to get tested, and hospital

2 | METHO DS

space limitation results in an increasing number of nonhospitalized
COVID‐19 patients. These patients are generally self‐quarantined with

2.1 | Patient consent

prescriptions for alternative medicine to help ameliorate their symptoms.
Most of the prescribed alternative medicines are, however, neither spe-

We have received consent from the patient to report this case.

cific nor highly effective for COVID‐19 treatment. There is an urgent
need of alternative medicine to help patients relieve symptoms during
self‐quarantine, and possibly to help increase their chances of survival

2.2 | Tests in hospitals

and recovery from the infection.
The outbreak of COVID‐19 in Wuhan, China, in January 2020, was

Blood routine examination and SARS‐CoV‐2 reverse transcription

the first strike on public health system by SARS‐CoV‐2.5 Patients in-

PCR (RT‐PCR) and antibody tests were performed by Wuhan Xiehe

fected with COVID‐19 had a high chance of developing severe pneu-

Hospital and Wuhan 161 Military Hospital, in the city of Wuhan,

monia and acute respiratory distress syndrome (16%‐17%) and the

China. The patient came to the clinic to seek medical help on

mortality rate was high (4.3%‐11%).3,5‐7 Hospitalization became the only

Jan 25th, 2020. On February 2nd, the patient's fingertip oxygen sa-

possible way for severe COVID‐19 patients to receive medical supports

turation dropped below 93% (Table 1) and computed tomography

and treatment against symptoms. The unexpected outbreak with a ra-

(CT) scans showed typical ground‐glass opacity, indicating severe

pidly growing patient number placed a significant demand of medical

viral pneumonia condition. Oropharyngeal swab samples were tested

resources, and so hospitals in Wuhan prioritized hospitalization for se-

negative for SARS‐CoV‐2 by RT‐PCR on January 28th, February

vere patients with positive PCR test results until mid‐February. A

2nd, February 26th, February 27th, March 14th, March 15th, and

number of patients in Wuhan had documented contact histories with

April 3rd. By the end of February, patient's symptoms were relieved
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T A B L E 1 Patient information, test results of IgM against common
pathogens, and vital conditions

62

Sex

Female

3 | RE SU LTS
3.1 | Patient information and conditions before
treatment with DG

Variable
Age, y

ET AL.

On January 12th (symptom onset day 1), 2020, the patient, a 62‐year‐old

Symptoms
Fever

Yes

female, started to feel persistent back pain and nausea, and additional

Dry cough

Yes

symptoms including fatigue and vomiting developed 1 week post symp-

Fatigue

Yes

tom onset. On January 25th (symptom onset day 14), she presented to an

Dyspnea

Yes

urgent care clinic in Wuhan, China, and later was discharged with Ce-

Headache

Yes

phalexin prescribed (orally 250 mg 3× daily). Her clinical condition did not

IgM specific for pathogens, on January 29th, 2020

improve. While back pain, nausea, fatigue and vomiting persisted, the

Influenza A virus

Negative

patient also developed persistent fevers (37.9℃‐39.3℃) starting on

Influenza B virus

Negative

Jan 26th (day 15), and shortness of breath starting on January 28th

Adenovirus

Negative

(day 17), which was further exacerbated 2 days later (Figure 1B). Given

Respiratory syncytial virus

Negative

the patient's ongoing fevers, Moxifloxacin (orally 400 mg 3× daily) and

Parainfluenza virus

Negative

Acetaminophen (orally 1000 mg 2× daily) were prescribed on Jan 27th

Mumps virus

Negative

Mycoplasma pneumoniae

Negative

Chlamydia pneumoniae

Negative

(symptom onset day 16), and Oseltamivir (orally 150 mg 3× daily) was
prescribed on Jan 31st (day 20). All treatments failed to control the
symptoms, and the patient developed a severe condition exhibiting

Vital signs, on February 2nd, 2020

shortness of breath (day 17). On Feb 2nd (day 22), the patient's fingertip

Temperature, ℃

39.2

Respiratory rate, breaths
per min

25

Heart rate (beats per min)

97

oxygen saturation dropped to 93% (comparable to severe COVID‐19
patients) and routine blood examination showed elevated level of
C‐reactive protein (50.02 in patient, vs normal ranges at 0‐4) (Table 1).
CT scan revealed bilateral distribution of patchy shadows and ground‐

SBP, mm Hg

120

DBP, mm Hg

80

Oxygen saturation

93%

Hematological and infection‐
related indices

Value

Normal
range

White blood cells, ×109/L

6.14

3.5‐9.5

Neutrophil, ×109/L

4.21

1.8‐6.3

Lymphocytes, ×109/L

1.63

1.1‐3.2

returned negative results as well (Table 1). Given the patient's history of

0.01

0.02‐0.52

contact with confirmed COVID‐19 patients and her typical COVID‐19

Basophil, ×10 /L

0

0.00‐0.06

Erythrocyte, ×109/L

4.3

3.8‐5.1

Hemoglobin, g/L

120

115‐150

February 2nd (symptom onset days 17 and 22). It is possible that, due to

Platelets, ×10 /L

234

125‐300

the tissue tropism of the viral replication, this patient did not have a

C‐reactive protein, mg/L

50.02

0‐4

D‐dimer, μg/mL

0.1

0‐0.5

9

Eosinophil, ×10 /L
9

9

glass opacity (Figure 1B, upper panel), typical hallmark of viral
pneumonia. On January 29th, sera test for IgM antibodies against common respiratory viruses that may induce viral pneumonia, including
influenza A, influenza B, adenovirus, respiratory syncytial virus,
parainfluenza, and mumps, all of which returned negative results
(Table 1). We also ruled out recent infections by mycoplasma pneumoniae and chlamydia pneumoniae, since IgM tests for these pathogens

symptoms, the most possible infection at the time was SARS‐CoV‐2.
However, the patient was tested negative by RT‐PCR for SARS‐CoV‐2

Note: Italic and bold values are significant parameters indicating a severe
COVID‐19 condition.

using samples collected via oropharyngeal swabbing, on January 28th and

vibrant viral growth in her upper respiratory system, which led to negative test results in RT‐PCR.8 During late January and early February,
the protocol for COVID‐19 clinical diagnosis and patient admission used
in China required a confirmation of infection by RT‐PCR positive result,
and thus this patient was not eligible for hospitalization at that moment.
This patient with suspected COVID‐19 was sent home for self‐

and gradually recovered, and on May 5th, the patient was tested

quarantine. Our medical team continued to follow‐up and treat this

positive with SARS‐CoV‐2‐specific IgG antibody.

patient during her quarantine at home.

2.3 | Treatments during self‐quarantine

3.2 | Alternative medicine treatment regimen
using DG

All medicines were prescribed by medical doctors in Wuhan
Xiehe Hospital and Wuhan 161 Military Hospital, and taken as

Given that the medicines prescribed in the hospital failed to relieve

instructed.

the patient's symptoms and started to trigger side effects, and that
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F I G U R E 1 Diammonium glycyrrhizinate+vitamin C as a potential treatment to relieve COVID‐19 symptoms. A, Chemical structures of
diammonium glycyrrhizinate and corticosteroid are shown. B, Symptoms and treatments of the patient outlined accordingly to days post
symptom onset since Jan 12th, 2020 [Color figure can be viewed at wileyonlinelibrary.com]

the patient was not eligible for COVID‐19 treatment in the hospital,

fibrosis. On May 5th, the patient was tested positive with SARS‐CoV‐

all prescribed medicines were discontinued. The patient was however

2‐specific IgG antibody, confirming her history of COVID‐19.

in urgent need of medical intervention. After discussion with several
physicians and professors who specialized in respiratory infectious
diseases, the patient decided to take DG (Figure 1A; orally 150 mg

4 | D IS C U S S I O N A N D C O N C L U S IO N S

3× daily) as an alternative medicine (symptom onset day 22). VC
(orally 200 mg 3× daily) was also empirically administered to reduce

Thus far for COVID‐19, there are no pharmacological treatment regi-

reactive oxygen species in inflammation and tissue injury. After

mens of proven efficacy. Immunopathology is a leading cause of mor-

12 hours after the first dose of DG+VC, severe symptoms including

bidity and mortality in severe COVID‐19 patients.9 There is an urgent

fever, shortness of breath, and coughing were relieved. Since

need for treatment regimens that can manage inflammation and tissue

February 3rd (day 23) the patient's clinical condition had been im-

damages associated with severe COVID‐19, to reduce mortality and

proved overtime. In brief: on February 3rd, the patient's body tem-

buy time for the immune system to clear the virus from the patients.

perature dropped below 37℃, vomiting stopped, and shortness of

During the initial COVID‐19 outbreak in Wuhan, corticosteroid has

breath and dry cough were significantly relieved to the levels that the

been used in hospitals to suppress lung inflammation in COVID‐19

patient did not notice for reporting; on February 4th, the patient

patients,10 however, multiple side effects have been observed. More-

stopped reporting nausea; on February 5th, back pain was resolved;

over, recent studies suggested limited clinical benefits of corticosteroid,

and on February 6th, the patient stopped feeling fatigued (Figure 1B).

yet the evidence for this remains largely circumstantial.11,12

In about a week, all severe symptoms were resolved, and the pa-

Here we report DG, a marketed Chinese traditional medicine with a

tient's appetite improved to the level comparable to her regular

steroid‐like effect, in combination with VC as a potential anti‐

appetite. After eight consecutive days with the DG+VC treatment

inflammatory treatment to relieve severe symptoms from COVID‐19. DG

regimen, on February 10th (day 30), the treatment was discontinued

is the active ingredient in the traditional Chinese medicinal herb licorice.

as the patient stopped reporting any discomforts.

It is metabolized into glycyrrhetinic acid, which has a chemical structure

We continued to monitor the patient's conditions. In follow‐up

similar to that of corticosteroid (Figure 1A) and thus functions as a

tests, she was tested negative for SARS‐CoV‐2 by RT‐PCR on

glucocorticoid‐like drug, which may help provide immune regulation

February 26th, February 27th, March 14th, March 15th, and

against cytokine storm and reduce inflammation, although might be less

April 3rd. CT scans on February 26th indicated significantly improved

stringent than steroids.13 DG has been used in the clinics for over

lung condition regarding signs of inflammation, and CT scans on April

20 years in China and Japan as an antiviral and anti‐inflammatory drug

3rd indicated complete resolution of lung inflammation despite minor

against hepatitis with few reported side effects, likely via its function in
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modulating the levels of expression of IL‐6 and IL‐10.14 Our previous
results also supported its safety and protective effects against colitis
using rat models.15 In an LPS‐induced lung acute injury model in mice,
DG exhibited potent anti‐inflammatory efficacy and attenuated lung
injury.16 Furthermore, DG has protective effects against Aβ1‐42‐induced
neurotoxicity.17 Last but not the least, it has been demonstrated that
glycyrrhizic acid derivatives have antiviral activity against SARS‐CoV infection in Vero cells.18 Our article here reports a case of nonhospital
COVID‐19 that showed significantly positive responses to DG treatment.
Although the exact functions of DG against SARS‐CoV‐2 infection and
the associated immunopathology await further investigations, it is
possible that the therapeutic effects of DG observed in this severe
COVID‐19 patient were a combinatory result of the antiviral and anti‐
inflammatory effects of DG in the respiratory and neurological systems.
Given these encouraging pharmacological effects and the demonstrated
safety, as well as the low cost and wide availability of DG and VC, we
suggest that a combination of these might be a good candidate for alternative medicine against COVID‐19. Implementation of this treatment
regimen might worth more attention, and further investigations in clinical
trials can be considered to validate its effects in relieving severe symptoms and reducing mortality of COVID‐19 in a larger cohort. For suspected COVID‐19 patients who cannot be hospitalized and have no
venues for COVID‐19 specific prescriptions, we suggest that the
combination of DG and VC may be a promising candidate as an alternative medicine to help relieve severe symptoms of COVID‐19 during
self‐quarantine.8
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